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Summary
Introduction: Enterobacteriaceae are rarely the etiologic agents of endocarditis, with Klebsiella
species being especially rare. From the end of 2005, isolates of carbapenem-resistant Klebsiella
pneumoniae began to appear in various hospitals across Israel, sensitive only to colistin and
gentamicin. We present a case of hospital-acquired endocarditis caused by carbapenem-resistant
K. pneumoniae in a young adult.
Case report: An 18-year-old man with 40% full thickness burns developed acute bacterial
endocarditis complicated by embolic myocardial infarction. Carbapenem-resistant K. pneumo-
niae carrying the blaKPC3 gene was isolated frommultiple blood cultures. He recovered fully after
antibiotic treatment with colistin and gentamicin.
Conclusions: To our knowledge, this is the first reported case of acute bacterial endocarditis
caused by carbapenem-resistant K. pneumoniae. The combination of intravenous colistin and
gentamicin was effective and resulted in the cure of this patient’s endocarditis without the need
for surgical intervention.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +972 2 677 6543; fax: +972 2 641 9545.
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1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.01.006Introduction
Klebsiella pneumoniae is a frequent cause of nosocomial
bloodstream infections where the primary source is usually
pneumonia, intravascular catheters or the urinary tract.Published by Elsevier Ltd. All rights reserved.
Table 1 Susceptibility results for the Klebsiella pneumo-
niae isolate
Antibiotic Susceptibility break
point, mg/mla
MIC mg/mlb
Colistin 4 0.5
Gentamicin 2 2.0
Tigecycline 1 1.5
Meropenem 4 >32
Imipenem 4 >32
Ertapenem 2 >32
MIC, minimum inhibitory concentration.
a CLSI breakpoints3 were used for the carbapenems and genta-
micin, the BSAC breakpoint for colistin (http://www.bsac.or-
g.uk), and the EUCAST value for tigecycline (http://
www.eucast.org). CLSI has no definitions for the latter two.
b Tested with E-test.
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biotics emerged among K. pneumoniae, including resistance
to the extended spectrum b-lactamases (ESBL), aminoglyco-
sides and fluoroquinolones, leaving carbapenems as the
agents of choice for the treatment of serious infections
caused by these organisms. In 2000, carbapenem-resistant
K. pneumoniae (CRKP) first appeared and spread rapidly in
New York City hospitals.1 In late 2005 a national epidemic of
nosocomial CRKP infections caused by a single strain, as
determined by pulsed-field electrophoresis (PFGE), emerged
in Israel. The epidemic strain was susceptible only to colistin
sulfomethate sodium and gentamicin.2
Herein we present our first recognized encounter with
the epidemic CRKP at our hospital–—a case that manifested
itself in an unusual way: acute myocardial infarction as the
presenting sign of infective endocarditis in a young adult.
The patient was successfully treated with colistin and
gentamicin.
Case presentation
A healthy 18-year-old man was admitted to plastic surgery
with 40% full thickness burns. On day 10 of his hospitalization,
he underwent skin grafts to his legs and abdomen. A Pseu-
domonas aeruginosa burn wound infection was treated with
cefepime through a peripheral venous catheter for five days
postoperatively. On the 17th hospital day, high fever, chest
pain, and shortness of breath supervened. On physical exam-
ination no obvious source of infection was seen. Hematolo-
gical investigations revealed a white blood cell count of
31.4  109/l with 95% neutrophils and a platelet count of
1085  109/l. The serum creatinine level was 65 mmol/l and
troponin was 3.47 (normal range 0—0.1 ng/ml). An electro-
cardiogram showed anterolateral ST elevation, consistent
with anteroseptal wall acute myocardial infarction. Trans-
thoracic echocardiography revealed segmental akinesis of
the anteroseptal walls and a large 24  19 mm mobile mass
under the mitral valve. Repeated peripheral blood cultures
taken 12 hours apart and a culture from a burned area grew
K. pneumoniae that was susceptible only to gentamicin and
colistin. He was diagnosed with hospital-acquired CRKP
mitral valve endocarditis with suspected emboli to the cor-
onary artery. The patient was treated with gentamicin
(1.7 mg/kg) and colistin (two million units), both every
8 hours. Trough plasma gentamicin levels were between 1
and 2 mg/ml. Because the patient was planned for additional
debridement of burns, with its attendant risk of repeated
bacteremic episodes, a decision was made in favor of con-
servative therapy of the endocarditis. After three weeks of
antibiotic treatment, acute renal failure developed (creati-
nine 427 mmol/l) and gentamicin treatment was stopped.
Colistin treatment was continued for a total duration of six
weeks and renal function returned to normal. Follow-up
blood cultures were negative. Echocardiography done one
year later showed billowing of the mitral valve, mildly global
hypokinesia of the left ventricle, and complete disappear-
ance of the vegetation.
Methods and results
Antibiotic susceptibilities were determined by disk diffusion
assay and also by Vitek-2 (BioMerieux Inc., Marcy l’Etoile,France). Minimum inhibitory concentrations (MICs) of carba-
penems, colistin, gentamicin and tigecycline were deter-
mined by E-test (AB Biodisk, Solna, Sweden). CLSI
breakpoints3 were used for carbapenems and gentamicin,
the BSAC breakpoint for colistin (http://www.bsac.org.uk),
and the EUCAST value for tigecycline (http://www.eucas-
t.org), since CLSI has no definitions for the latter two. The
susceptibility results for the K. pneumoniae isolate are pre-
sented in Table 1. The isolate was resistant to cephalosporins,
piperacillin/tazobactam, quinolones and amikacin, as well as
highly resistant to carbapenems. The organism was suscep-
tible only to colistin and gentamicin with intermediate sus-
ceptibility to tigecycline.
Genomic DNA of the clinical isolate was analyzed by PFGE
and revealed a SpeI endonuclease-restricted DNA profile
identical to clone Q, the major CRKP clone reported in
Israel.2 Identification of carbapenemase genes was per-
formed on cell lysates by PCR using specific primers designed
to identify known class A b-lactamase genes, including
blaKPC, blaSME, blaIMI, and blaNMC, as previously described.
4
The K. pneumoniae isolate had the carbapenemase gene
blaKPC, which was characterized by nucleotide acid and
deduced protein sequences as KPC-3.
Discussion
We have presented what is, to the best of our knowledge, the
first reported case of endocarditis caused by carbapenem-
resistant K. pneumoniae. We assume that the source of the
CRKP bacteremia was preceding burned skin colonization.
PFGE showed the isolate to be identical to the epidemic
Israeli clone of CRKP, carrying the KPC-3 gene. Infection by
this resistant pathogen is an emerging problem in hospitals
across Israel; it mainly affects the elderly and is a predictor of
death.5 There are few antibiotic options because it is sus-
ceptible only to colistin and gentamicin and on the break-
point of susceptibility to tigecycline, as demonstrated by the
present case.
Detection of KPC-mediated resistance to carbapenems by
some routine clinical microbiology techniques is not straight-
forward. Some automated and non-automated methods have
sensitivities for KPC detection as low as about 40% when
imipenem or meropenem are tested alone.6,7 Among the
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sensitivities and specificities of90% and84%, respectively,
by a range of methods. Hence, ertapenem should be included
in susceptibility testing of all clinical isolates of Enterobac-
teriaceae.
Endocarditis is a rare complication of major burn injury,
with an incidence of 1.3% in one study.8 Although non-
salmonella Enterobacteriaceae are common pathogens in
nosocomial bloodstream infections, they rarely cause endo-
carditis, possibly due to their low affinity to endocardial
tissue.9 K. pneumoniae endocarditis is particularly rare, yet,
the associated mortality is 49%.10 When endocarditis is
caused by an ESBL-producing K. pneumoniae, a carbapenem
is likely the antibiotic of choice.11 Because many patients
fail to respond to medical treatment alone, early cardiac
surgery, in combination with prolonged courses of combined
antibiotic therapy, is a cornerstone of treatment.12 The
choice of a combination of gentamicin and colistin in our
patientwas based on the lack of other options and the dearth
of information regarding monotherapy with either agent
alone.
Gentamicin monotherapy was not effective in sterilizing
vegetations caused by Enterobacteriaceae in animal models
of infective endocarditis, but was synergistic with cell wall
active drugs in clearing the infection.13,14 Thus, a combina-
tion of gentamicin with a b-lactam is recommended for K.
pneumoniae endocarditis.12 Data on the efficacy of colistin
for the treatment of endocarditis are scarce. The in vivo
activity of colistin was evaluated in an experimental rabbit
model of Acinetobacter baumannii endocarditis with a strain
susceptible to colistin and intermediate to imipenem. Com-
pared to a control group, colistin was effective ( p < 0.05) in
bacterial clearance from the blood, but was less effective in
clearing the bacteria from vegetations.15 Colistin increases
the permeability of the outer membrane of Gram-negative
bacteria, thereby it might be synergistic with other antibio-
tics, such as aminoglycosides, by facilitating the penetration
of the latter through the membrane. Few clinical studies
have evaluated the synergistic activity of colistin with other
antimicrobial agents; most of them are limited by the lack of
a control group. There are two case reports of successful
treatment of P. aeruginosa endocarditis by a regimen
comprising colistin with either tobramycin and rifampin or
amikacin.16,17 Another antimicrobial regimen that has
demonstrated synergy against CRKP during in vitro testing
is the combination of polymyxin B and rifampin.18 Since CRKP
isolates are not universally susceptible to polymyxin and
gentamicin, the therapeutic regimens should definitely be
based on isolate-specific susceptibility data.
The most notable finding of the present study is that the
combination of colistin and gentamicin was effective and
resulted in the cure of this patient’s endocarditis, without
the need for surgical intervention. In the era of multi-drug
resistance, this combination, which should be given cau-
tiously because of its nephrotoxic potential, is a rational
option for severe infections.
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